Janux Therapeutics (JANX) Enterprise Value (2020 - 2025)
Janux Therapeutics (JANX) has disclosed Enterprise Value for 6 consecutive years, with -$966.6 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 5.72% to -$966.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$966.6 million through Dec 2025, up 5.72% year-over-year, with the annual reading at -$966.6 million for FY2025, 5.72% up from the prior year.
- Enterprise Value for Q4 2025 was -$966.6 million at Janux Therapeutics, up from -$989.0 million in the prior quarter.
- The five-year high for Enterprise Value was -$303.3 million in Q2 2023, with the low at -$1.0 billion in Q4 2024.
- Average Enterprise Value over 5 years is -$584.6 million, with a median of -$394.2 million recorded in 2021.
- The sharpest move saw Enterprise Value tumbled 4699.24% in 2021, then skyrocketed 51.34% in 2022.
- Over 5 years, Enterprise Value stood at -$375.0 million in 2021, then increased by 12.79% to -$327.0 million in 2022, then decreased by 5.2% to -$344.0 million in 2023, then crashed by 197.99% to -$1.0 billion in 2024, then grew by 5.72% to -$966.6 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods came in at -$966.6 million, -$989.0 million, and -$996.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.